Stay updated with breaking news from Liminal Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Termination results in anticipated cash savings of $33.1 millionRemoves last of legacy contracts associated with former plasma-derived therapeutics businessLAVAL, QC and CAMBRIDGE, ENGLAND,
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announced today...
$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras developmentNet loss from continuing operations of $6.5 million during the quarter ended June 30, 2022
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of...
/PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of...